• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Product Image

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling.
There are today 242 companies plus partners developing 339 T cell receptor pathway targeting drugs in 1232 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 173 drugs. T Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 201 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 196 out of the 199 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 46 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos